Barclays PLC Has $439,000 Stake in Solid Biosciences Inc. (NASDAQ:SLDB)

Barclays PLC increased its stake in Solid Biosciences Inc. (NASDAQ:SLDB) by 412.1% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 62,856 shares of the company’s stock after purchasing an additional 50,582 shares during the quarter. Barclays PLC’s holdings in Solid Biosciences were worth $439,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the stock. Dimensional Fund Advisors LP increased its stake in Solid Biosciences by 8.1% in the second quarter. Dimensional Fund Advisors LP now owns 70,827 shares of the company’s stock valued at $402,000 after purchasing an additional 5,287 shares in the last quarter. MetLife Investment Management LLC grew its stake in shares of Solid Biosciences by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 13,699 shares of the company’s stock valued at $95,000 after buying an additional 7,719 shares during the period. American Century Companies Inc. increased its position in Solid Biosciences by 39.9% in the 2nd quarter. American Century Companies Inc. now owns 34,557 shares of the company’s stock valued at $196,000 after buying an additional 9,853 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in Solid Biosciences during the 3rd quarter worth approximately $71,000. Finally, Point72 DIFC Ltd bought a new position in Solid Biosciences in the second quarter worth approximately $58,000. Institutional investors and hedge funds own 81.46% of the company’s stock.

Insider Activity

In other news, insider Jessie Hanrahan sold 4,610 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $5.60, for a total transaction of $25,816.00. Following the completion of the sale, the insider now owns 14,235 shares in the company, valued at $79,716. This trade represents a 24.46 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Alexander Cumbo sold 11,114 shares of the company’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $5.60, for a total value of $62,238.40. Following the completion of the transaction, the chief executive officer now owns 38,484 shares in the company, valued at approximately $215,510.40. The trade was a 22.41 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 23,719 shares of company stock valued at $135,457 in the last ninety days. 13.63% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. JPMorgan Chase & Co. decreased their price objective on Solid Biosciences from $15.00 to $12.00 and set an “overweight” rating for the company in a report on Tuesday, November 12th. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Solid Biosciences in a research note on Thursday, December 12th. Wedbush began coverage on shares of Solid Biosciences in a research note on Friday, December 13th. They issued an “outperform” rating and a $16.00 price objective on the stock. Citizens Jmp upgraded shares of Solid Biosciences to a “strong-buy” rating in a report on Tuesday, December 10th. Finally, Chardan Capital restated a “buy” rating and issued a $15.00 target price on shares of Solid Biosciences in a report on Monday, November 11th. Eight equities research analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $15.22.

Solid Biosciences Stock Performance

NASDAQ:SLDB opened at $4.14 on Friday. Solid Biosciences Inc. has a 52 week low of $3.85 and a 52 week high of $15.05. The firm has a 50-day moving average price of $5.06 and a two-hundred day moving average price of $6.69. The firm has a market cap of $165.41 million, a price-to-earnings ratio of -1.36 and a beta of 2.01.

Solid Biosciences (NASDAQ:SLDB) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.12). As a group, sell-side analysts forecast that Solid Biosciences Inc. will post -2.85 earnings per share for the current year.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.